Iambic Therapeutics and Revolution Medicines entered a multi-year partnership integrating Iambic's AI-driven NeuralPLexer platform with Revolution’s proprietary oncology data. The collaboration aims to rapidly identify drug candidates targeting hard-to-drug cancer proteins using advanced protein-ligand interaction models. Valued at up to $25 million in upfront and milestone payments, this partnership exemplifies the increasing role of artificial intelligence in streamlining early-stage drug discovery. Additionally, Novartis exercised an option deal worth $175 million with Sironax Biotechnology for blood-brain barrier crossing technologies, further emphasizing AI and advanced modalities in drug development.